Cargando…
Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome
PURPOSE: To determine the ocular and systemic safety of using topical Lambda-Cyhalothrin (LCL) in a canine model of infantile nystagmus syndrome (INS). The rationale for this proposal is based on a case study of a patient whose INS improved after inadvertent ocular exposure to a pyrethroid pesticide...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728007/ https://www.ncbi.nlm.nih.gov/pubmed/32971638 http://dx.doi.org/10.4103/ijo.IJO_586_20 |
_version_ | 1783621176566743040 |
---|---|
author | Hertle, Richard W Dell'Osso, Louis F Jacobs, Jonathan B Yang, Dongsheng Dumire, Jeffery Evano-Chapman, Michelle |
author_facet | Hertle, Richard W Dell'Osso, Louis F Jacobs, Jonathan B Yang, Dongsheng Dumire, Jeffery Evano-Chapman, Michelle |
author_sort | Hertle, Richard W |
collection | PubMed |
description | PURPOSE: To determine the ocular and systemic safety of using topical Lambda-Cyhalothrin (LCL) in a canine model of infantile nystagmus syndrome (INS). The rationale for this proposal is based on a case study of a patient whose INS improved after inadvertent ocular exposure to a pyrethroid pesticide containing LCL. METHODS: After in-vitro safety testing and IUCAC approval, we studied increasing concentrations of topical LCL drops (0.002% to 0.07%) in canines with a purposely bred defect in the RPE65 gene resulting in both retinal degeneration and INS. We collected data on ocular and systemic effects and performed eye-movement recordings (EMR). RESULTS: At the 0.07% concentration dose of LCL, there was minimal, reversible, conjunctival hyperemia. There was no other ocular or systemic toxicity. At the 0.06% dose, there was a visible decrease in the INS and EMR showed a 153%–240% increase in the nystagmus acuity function and a 30%–70% decrease in amplitude across gaze. There was also a 40%–60% decrease in intraocular pressure while on the drop in both eyes. CONCLUSION: This animal study suggests this new pharmacological agent has potential for topical treatment of both INS and diseases with raised intraocular pressure. Further, this new treatment approach confirms the importance of extraocular muscle proprioception in ocular motor diseases and their treatment. |
format | Online Article Text |
id | pubmed-7728007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-77280072020-12-11 Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome Hertle, Richard W Dell'Osso, Louis F Jacobs, Jonathan B Yang, Dongsheng Dumire, Jeffery Evano-Chapman, Michelle Indian J Ophthalmol Original Article PURPOSE: To determine the ocular and systemic safety of using topical Lambda-Cyhalothrin (LCL) in a canine model of infantile nystagmus syndrome (INS). The rationale for this proposal is based on a case study of a patient whose INS improved after inadvertent ocular exposure to a pyrethroid pesticide containing LCL. METHODS: After in-vitro safety testing and IUCAC approval, we studied increasing concentrations of topical LCL drops (0.002% to 0.07%) in canines with a purposely bred defect in the RPE65 gene resulting in both retinal degeneration and INS. We collected data on ocular and systemic effects and performed eye-movement recordings (EMR). RESULTS: At the 0.07% concentration dose of LCL, there was minimal, reversible, conjunctival hyperemia. There was no other ocular or systemic toxicity. At the 0.06% dose, there was a visible decrease in the INS and EMR showed a 153%–240% increase in the nystagmus acuity function and a 30%–70% decrease in amplitude across gaze. There was also a 40%–60% decrease in intraocular pressure while on the drop in both eyes. CONCLUSION: This animal study suggests this new pharmacological agent has potential for topical treatment of both INS and diseases with raised intraocular pressure. Further, this new treatment approach confirms the importance of extraocular muscle proprioception in ocular motor diseases and their treatment. Wolters Kluwer - Medknow 2020-10 2020-09-23 /pmc/articles/PMC7728007/ /pubmed/32971638 http://dx.doi.org/10.4103/ijo.IJO_586_20 Text en Copyright: © 2020 Indian Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Hertle, Richard W Dell'Osso, Louis F Jacobs, Jonathan B Yang, Dongsheng Dumire, Jeffery Evano-Chapman, Michelle Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title | Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title_full | Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title_fullStr | Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title_full_unstemmed | Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title_short | Topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
title_sort | topical lambda-cyhalothrin in reducing eye oscillations in a canine model of infantile nystagmus syndrome |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728007/ https://www.ncbi.nlm.nih.gov/pubmed/32971638 http://dx.doi.org/10.4103/ijo.IJO_586_20 |
work_keys_str_mv | AT hertlerichardw topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome AT dellossolouisf topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome AT jacobsjonathanb topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome AT yangdongsheng topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome AT dumirejeffery topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome AT evanochapmanmichelle topicallambdacyhalothrininreducingeyeoscillationsinacaninemodelofinfantilenystagmussyndrome |